Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.
Advertisement

Related Content

Mylan Gears Up To Launch US Advair Rival This Month
Mylan’s Nod For US Advair Rival Puts It A Year Ahead Of The Pack
Mylan’s Generic Advair Approval Showcases US FDA Efforts To Boost Complex Products
Generic Advair: Finally Approved, A Long Time Coming
Alkermes' Depression Drug Likely Needs Another Trial After Crushing US Advisory Cmte. Vote
Alkermes Depression Drug Faces Tough Questions At US FDA Advisory Committee
Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
US FDA Releases Slew Of Guidances On A Fell Day For Complex Generics
Advair Bioequivalence Guidance Falls Short of GSK’s Requests

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel